About AEON BioPharma
AEON BioPharma is a company based in Newport Beach (United States) founded in 2018. AEON BioPharma has raised $30 million across 2 funding rounds from investors including Daewoong Pharmaceutical. The company has 5 employees as of December 31, 2024. AEON BioPharma offers products and services including ABP-450. AEON BioPharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Newport Beach, United States
- Employees 5 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aeon Biopharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
$42.01 M (USD)110.92as on Dec 31, 2024
-
EBITDA
-$27.73 M (USD)47.42as on Dec 31, 2024
-
Total Equity Funding
$30 M (USD)
in 2 rounds
-
Latest Funding Round
$54.5 M (USD), Post-IPO
Aug 10, 2022
- Investors
-
Employee Count
5
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AEON BioPharma
AEON BioPharma is a publicly listed company on the AMEX with ticker symbol AEON in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AEON BioPharma
AEON BioPharma offers a comprehensive portfolio of products and services, including ABP-450.
Neurotoxin treatment for nerve and muscle-based disorders
People of AEON BioPharma
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of AEON BioPharma
AEON BioPharma has successfully raised a total of $30M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $54.5 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AEON BioPharma
AEON BioPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Daewoong Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapies for gastrointestinal disorders and related diseases are developed.
|
Locked | Locked | Locked |
Investor details for AEON BioPharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AEON BioPharma
Investment portfolio details for AEON BioPharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AEON BioPharma
Detailed financials for AEON BioPharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aeon Biopharma Comparisons
Peer comparison for AEON BioPharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AEON BioPharma
AEON BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of AEON BioPharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aeon Biopharma
Complete news archive for AEON BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AEON BioPharma
AEON BioPharma was founded in 2018 and raised its 1st funding round 2 years after it was founded.
AEON BioPharma is headquartered in Newport Beach, United States. It is registered at Newport Beach, California, United States.
Marc Forth is the current CEO of AEON BioPharma.
AEON BioPharma is a funded company, having raised a total of $30M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at AEON BioPharma is 5.
AEON BioPharma was founded in 2018 and is headquartered in Newport Beach, United States. Bio-therapeutics targeted at nervous system-related conditions are developed by the company within the biopharmaceutical sector. Operations focus on innovative treatments, including the flagship product ABP-450, a 900 kDa prabotulinumtoxinA formulation. This product is utilized for managing disabling disorders in patients, with ongoing efforts centered on clinical advancement and therapeutic delivery.
AEON BioPharma's top competitors include Jazz Pharmaceuticals, Flexion Therapeutics and PTC Therapeutics.
AEON BioPharma offers ABP-450.
Yes, AEON BioPharma is publicly traded on AMEX under the ticker symbol AEON.
AEON BioPharma has 1 investor. Key investors include Daewoong Pharmaceutical.
The ticker symbol of AEON BioPharma is AEON on AMEX.